利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

27 条记录 (耗时 0.037 秒)

    Substituted bicyclic and tricyclic thieno[2,3-d]pyrimidines as A2A adenosine receptor antagonists
    11.
    发明授权
    Substituted bicyclic and tricyclic thieno[2,3-d]pyrimidines as A2A adenosine receptor antagonists 有权
    取代的双环和三环噻吩并[2,3-d]嘧啶作为A2A腺苷受体拮抗剂

    公开(公告)号：US07776868B2

    公开(公告)日：2010-08-17

    申请号：US11947690

    申请日：2007-11-29

    申请人： Tetsuya Kobayashi ,  Rao Kalla ,  Elfatih Elzein ,  Jeff Zablocki ,  Brent Blackburn

    发明人： Tetsuya Kobayashi ,  Rao Kalla ,  Elfatih Elzein ,  Jeff Zablocki ,  Brent Blackburn

    IPC分类号： C07D495/04 ,  A61K31/519 ,  A61P25/28 ,  A61P25/24 ,  A61P3/04 ,  A61P37/02

    CPC分类号： C07D495/04

    摘要： The present invention relates to novel compounds that are A2A adenosine receptor antagonists having the structure of Formula I and to their use in treating mammals for various disease states, such as obesity, CNS disorders, including the “movement disorders” (Parkinson's disease, Huntington's Chorea, and catelepsy), and cerebral ischemia, excitotoxicity, cognitive and physiological disorders, depression, ADHD, and drug addiction (alcohol, amphetamine, cannabinoids, cocaine, nicotine, and opioids) and to their use in the enhancement of immune response. The invention also relates to methods for the preparation of such compounds, and to pharmaceutical compositions containing them.

    摘要翻译： 本发明涉及具有式I结构的A2A腺苷受体拮抗剂的新化合物及其用于治疗各种疾病状态的哺乳动物，例如肥胖症，中枢神经系统疾病，包括“运动障碍”（帕金森病，亨廷顿氏舞蹈病 ，和脑损伤）和脑缺血，兴奋性毒性，认知和生理障碍，抑郁症，ADHD和药物成瘾（酒精，苯丙胺，大麻素，可卡因，尼古丁和阿片样物质）及其在增强免疫应答中的用途。 本发明还涉及制备这些化合物的方法以及含有它们的药物组合物。

    A2A ADENOSINE RECEPTOR ANTAGONISTS
    13.
    发明申请
    A2A ADENOSINE RECEPTOR ANTAGONISTS 有权
    A2A腺苷受体拮抗剂

    公开(公告)号：US20080188495A1

    公开(公告)日：2008-08-07

    申请号：US11947690

    申请日：2007-11-29

    申请人： Tetsuya Kobayashi ,  Rao Kalla ,  Elfatih Elzein ,  Jeff Zablocki ,  Brent Blackburn

    发明人： Tetsuya Kobayashi ,  Rao Kalla ,  Elfatih Elzein ,  Jeff Zablocki ,  Brent Blackburn

    IPC分类号： A61K31/519 ,  C07D495/04 ,  A61P1/16 ,  A61P25/30 ,  A61P25/00 ,  A61P25/16

    CPC分类号： C07D495/04

    摘要： The present invention relates to novel compounds that are A2A adenosine receptor antagonists, and to their use in treating mammals for various disease states, such as CNS disorders, including the “movement disorders” (Parkinson's disease, Huntington's Chorea, and catalepsy), and cerebral ischemia, excitotoxicity, cognitive and physiological disorders, depression, ADHD, hepatic fibrosis, cirrhosis of the liver, and drug addiction (alcohol, amphetamine, cannabinoids, cocaine, nicotine, and opioids) and to their use in the enhancement of immune response. The invention also relates to methods for the preparation of such compounds, and to pharmaceutical compositions containing them.

    摘要翻译： 本发明涉及作为Aβ2A腺苷受体拮抗剂的新化合物及其用于治疗各种疾病状态的哺乳动物，例如CNS障碍，包括“运动障碍”（Parkinson's disease，Huntington's 胆碱和僵住症）和脑缺血，兴奋性毒性，认知和生理障碍，抑郁症，ADHD，肝纤维化，肝硬化和药物成瘾（酒精，苯丙胺，大麻素，可卡因，尼古丁和阿片样物质）及其使用 在增强免疫反应。 本发明还涉及制备这些化合物的方法以及含有它们的药物组合物。

    METHOD OF REVERSING LEFT VENTRICULAR REMODELING
    20.
    发明申请
    METHOD OF REVERSING LEFT VENTRICULAR REMODELING 审中-公开
    逆向左心室重建的方法

    公开(公告)号：US20090176772A1

    公开(公告)日：2009-07-09

    申请号：US12393952

    申请日：2009-02-26

    申请人： Brent Blackburn ,  Hani Sabbah

    发明人： Brent Blackburn ,  Hani Sabbah

    IPC分类号： A61K31/5415 ,  A61K31/495 ,  A61P9/00

    CPC分类号： A61K45/06 ,  A61K31/495 ,  A61K2300/00

    摘要： The present invention relates to method of reversing left ventricle remodeling by combined administration of therapeutically effective amounts ranolazine and at least one co-remodeling agent, which may be an ACE inhibitor, an ARB, or a beta-blocker. The method finds utility in the treatment of heart failure. This invention also relates to pharmaceutical formulations that are suitable for such combined administration.

    摘要翻译： 本发明涉及通过联合施用治疗有效量的雷洛嗪和至少一种共重塑剂（其可以是ACE抑制剂，ARB或β-阻断剂）逆转左心室重塑的方法。 该方法可用于治疗心力衰竭。 本发明还涉及适合于这种组合给药的药物制剂。